INZY Stock Price, Inozyme Pharma, Inc. Quote, Chart

Market Summary

USD4.65+0.04

Market Closed

0.87%

INZY Stock Price

View Fullscreen

INZY RSI Chart

INZY Valuation

Market Cap

287.2M

Price/Earnings (Trailing)

-4.04

Price/Free Cashflow

-4.05

INZY Price/Sales (Trailing)

INZY Profitability

Return on Equity

-50.66%

Return on Assets

-35.43%

Free Cashflow Yield

-24.71%

INZY Fundamentals

INZY Earnings

Earnings (TTM)

-71.2M

Earnings Growth (Yr)

-16.18%

Earnings Growth (Qtr)

-29.49%

Breaking Down INZY Revenue

Last 7 days

7.4%

Last 30 days

-32.9%

Last 90 days

-12.4%

Trailing 12 Months

-20.1%

How does INZY drawdown profile look like?

INZY Financial Health

Current Ratio

13.36

Debt/Equity

0.32

Debt/Cashflow

-1.58

INZY Investor Care

Shares Dilution (1Y)

52.91%

Diluted EPS (TTM)

-1.38

Tracking the Latest Insider Buys and Sells of Inozyme Pharma, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 02, 2024	treco douglas a	sold	-52,209	6.94	-7,523	ceo
Apr 01, 2024	treco douglas a	acquired	-	-	25,000	ceo
Mar 28, 2024	winton matthew	acquired	10,616	3.33	3,188	coo
Sep 29, 2023	subramanian sanjay	acquired	8,278	3.57	2,319	svp, cfo
Aug 01, 2023	pivotal bioventure partners fund i, l.p.	bought	4,000,000	4.8	833,333	-
Aug 01, 2023	hopfner robert lorne	bought	4,000,000	4.8	833,333	-
May 12, 2023	hopfner robert lorne	bought	1,429,390	6.25	228,702	-
May 11, 2023	hopfner robert lorne	bought	1,420,610	6.48	219,230	-
Mar 31, 2023	subramanian sanjay	acquired	2,163	2.21	979	svp, cfo
Mar 31, 2023	bolte axel	acquired	10,621	2.21	4,806	-

Which funds bought or sold INZY recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 30, 2024	Avior Wealth Management, LLC	new	-	68.00	68.00	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	1,000	1,000	-%
Apr 25, 2024	Bank of New York Mellon Corp	added	4.06	586,408	1,259,550	-%
Apr 23, 2024	Values First Advisors, Inc.	sold off	-100	-59,207	-	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-61.35	-4,000	9,000	-%
Apr 23, 2024	BFSG, LLC	new	-	3,830	3,830	-%
Apr 22, 2024	MetLife Investment Management, LLC	added	46.98	37,173	112,920	-%
Apr 19, 2024	DENALI ADVISORS LLC	unchanged	-	74,800	168,520	0.05%
Apr 16, 2024	Overbrook Management Corp	unchanged	-	745,708	1,680,040	0.45%

Are Funds Buying or Selling INZY?

Are funds buying INZY calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own INZY

No. of Funds

Unveiling Inozyme Pharma, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 20, 2024	sofinnova venture partners x, l.p.	6.9%	4,280,308	SC 13D/A
Feb 14, 2024	deep track capital, lp	0%	0	SC 13G/A
Feb 14, 2024	new enterprise associates 15, l.p.	-	0	SC 13G/A
Feb 14, 2024	venrock healthcare capital partners ii, l.p.	0.0%	0	SC 13G/A
Feb 14, 2024	rock springs capital management lp	5.96%	3,681,174	SC 13G/A
Feb 14, 2024	eventide asset management, llc	5.15%	3,179,837	SC 13G
Feb 14, 2024	samlyn capital, llc	5.5%	3,372,558	SC 13G
Feb 14, 2024	baker bros. advisors lp	0.0%	0	SC 13G/A
Feb 12, 2024	pivotal bioventure partners fund i, l.p.	4.7%	2,923,110	SC 13D/A
Feb 07, 2024	adage capital partners gp, l.l.c.	8.97%	5,537,500	SC 13G/A

Recent SEC filings of Inozyme Pharma, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 08, 2024	8-K	Current Report
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Mar 15, 2024	4	Insider Trading
Mar 15, 2024	4	Insider Trading
Mar 15, 2024	4	Insider Trading
Mar 12, 2024	S-8	Employee Benefits Plan

Peers (Alternatives to Inozyme Pharma, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

Inozyme Pharma, Inc. News

Latest updates

Inozyme Pharma, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	-2.4%	201	206	151	142	139	154	162	109	124	138	148	159	169	179	69.00	48.00
Current Assets	-2.3%	196	201	144	134	131	146	154	101	115	131	141	148	151	164	65.00	47.00
Cash Equivalents	-26.2%	35.00	47.00	41.00	49.00	33.00	44.00	63.00	32.00	23.00	27.00	26.00	16.00	28.00	60.00	51.00	32.00
Net PPE	-7.4%	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00	3.00	3.00	3.00	2.00	1.00	0.00
Liabilities	32.7%	60.00	45.00	45.00	38.00	21.00	19.00	13.00	15.00	14.00	12.00	10.00	10.00	11.00	11.00	7.00	3.00
Current Liabilities	19.6%	15.00	12.00	12.00	13.00	15.00	13.00	11.00	12.00	12.00	9.00	7.00	7.00	10.00	10.00	7.00	3.00
Long Term Debt	39.6%	45.00	32.00	13.00	24.00	4.00	4.00	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-12.3%	140	160	106	103	118	135	149	94.00	109	126	138	149	158	168	-	-
Retained Earnings	-8.1%	-285	-264	-247	-232	-214	-196	-179	-164	-147	-128	-114	-102	-91.08	-79.96	-51.86	-34.65
Additional Paid-In Capital	0.4%	426	425	353	336	333	331	329	259	257	255	253	251	249	248	2.00	1.00
Shares Outstanding	0.0%	62.00	62.00	46.00	44.00	40.00	44.00	40.00	24.00	24.00	24.00	23.00	23.00	23.00	-	-	-
Float	-	-	-	199,466	-	-	-	128	-	-	-	245	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Cashflow From Operations	2.0%	-18,487	-18,868	-15,548	-17,772	-14,400	-14,514	-14,687	-14,160	-13,444	-12,300	-10,033	-12,376	-10,875	-10,201	-8,633	-6,265	-	-	-
Share Based Compensation	0.1%	1,673	1,672	1,600	2,092	1,886	1,849	2,185	1,752	2,022	1,752	1,813	1,577	1,273	786	120	129	-	107	40.00
Cashflow From Investing	85.5%	-6,470	-44,615	-16,327	13,766	3,218	-8,257	-22,926	22,562	9,487	13,062	19,674	573	-19,957	-99,666	5,852	-3,408	-	-	-
Cashflow From Financing	-82.0%	12,516	69,715	23,642	20,096	-	4,215	68,333	240	11.00	237	112	249	-986	118,861	31,932	5.00	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

INZY Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 54,847	$ 47,849
General and administrative	20,798	20,826
Total operating expenses	75,645	68,675
Loss from operations	(75,645)	(68,675)
Other income (expense):
Interest income	7,837	2,195
Interest expense	(3,333)	(262)
Other expense, net	(28)	(319)
Other income, net	4,476	1,614
Net loss	(71,169)	(67,061)
Other comprehensive income (loss):
Unrealized (losses) on available-for-sale securities	264	(198)
Foreign currency translation adjustment	(18)	(25)
Total other comprehensive income (loss)	246	(223)
Comprehensive loss	(70,923)	(67,284)
Net Income (Loss)	$ (71,169)	$ (67,061)
Net loss per share attributable to common stockholder - basic	$ (1.37)	$ (1.78)
Net loss per share attributable to common stockholders- diluted	$ (1.37)	$ (1.78)
Weighted-average common shares outstanding - basic	51,839,131	37,763,168
Weighted-average common shares outstanding - diluted	51,839,131	37,763,168

INZY Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 34,588	$ 32,915
Short-term investments	154,001	94,951
Prepaid expenses and other current assets	7,661	3,527
Total current assets	196,250	131,393
Property and equipment, net	1,466	2,018
Right-of-use assets	1,126	1,620
Restricted Cash, Noncurrent	311	354
Prepaid expenses, net of current portion	1,694	3,810
Total assets	200,847	139,195
Current liabilities:
Accounts payable	1,166	2,544
Accrued expenses	12,610	11,355
Operating lease liabilities	910	816
Total current liabilities	14,686	14,715
Operating lease liabilities, net of current portion	913	1,823
Long term debt, net	44,769	4,139
Other long term liabilities	0	124
Total liabilities	60,368	20,801
Commitments and contingencies (Note 7)
Stockholders' equity
Preferred Stock, $0.0001 par value - 5,000,000 shares authorized at December 31, 2023 and December 31, 2022; No shares issued and outstanding at December 31, 2023 or December 31, 2022	0	0
Common Stock, $0.0001 par value - 200,000,000 shares authorized at December 31, 2023 and December 31, 2022; 61,768,771 shares issued and outstanding at December 31, 2023 and 40,394,363 shares issued and outstanding at December 31, 2022	6	4
Additional paid in-capital	426,362	333,356
Accumulated other comprehensive (loss) income	41	(205)
Accumulated deficit	(285,930)	(214,761)
Total stockholders' equity	140,479	118,394
Total liabilities and stockholders' equity	$ 200,847	$ 139,195

About Inozyme Pharma, Inc.

Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases in the United States. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein, which is in Phase 1/2 clinical trials for the treatment of ENPP1 and ABCC6 deficiency, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

CEO	Dr. Douglas A. Treco Ph.D.
WEBSITE	inozyme.com
INDUSTRY	Biotechnology
EMPLOYEES	56

Inozyme Pharma, Inc. Frequently Asked Questions

What is the ticker symbol for Inozyme Pharma, Inc.? What does INZY stand for in stocks?

INZY is the stock ticker symbol of Inozyme Pharma, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Inozyme Pharma, Inc. (INZY)?

As of Thu May 02 2024, market cap of Inozyme Pharma, Inc. is 287.22 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INZY stock?

You can check INZY's fair value in chart for subscribers.

What is the fair value of INZY stock?

You can check INZY's fair value in chart for subscribers. The fair value of Inozyme Pharma, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Inozyme Pharma, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for INZY so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Inozyme Pharma, Inc. a good stock to buy?

The fair value guage provides a quick view whether INZY is over valued or under valued. Whether Inozyme Pharma, Inc. is cheap or expensive depends on the assumptions which impact Inozyme Pharma, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INZY.